Botulinum Toxin for Rhinitis

Current Allergy and Asthma Reports

Volumn 16, Issue 8, 2016, Pages

  Ozcan, Cengiz ^a   Ismi, Onur ^a  

^a MERSIN UNIVERSITY   (Turkey)

Author keywords

Allergic rhinitis; Botulinum toxin A; Idiopathic rhinitis; Rhinitis; Vasomotor rhinitis

Indexed keywords

BOTULINUM TOXIN A; CETIRIZINE; IPRATROPIUM BROMIDE; TRIAMCINOLONE; MUSCLE RELAXANT AGENT;

ALLERGIC RHINITIS; BLURRED VISION; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRY NOSE; EPISTAXIS; HUMAN; IDIOPATHIC RHINITIS; NONHUMAN; NOSE OBSTRUCTION; REVIEW; RHINITIS; RHINORRHEA; SINGLE DRUG DOSE; SNEEZING; SOMNOLENCE; INTRANASAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; BOTULINUM TOXINS, TYPE A; HUMANS; NEUROMUSCULAR AGENTS; RHINITIS; TREATMENT OUTCOME;

EID: 84979608122     PISSN: 15297322     EISSN: 15346315     Source Type: Journal    
DOI: 10.1007/s11882-016-0636-3     Document Type: Review

References (36)

1. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and Its Impact on Asthma (ARIA) 2008 update in collaboration with the World Health Organization, GA(2)LEN and AllerGen. Allergy. 2008;63 suppl 86:8–160. This report is about updating the new classification of allergic rhinitis.
2. International Consensus Report on Diagnosis and Management of Rhinitis. International Rhinitis Management Working Group. Allergy. 1994;49 Suppl 19:1–34.
3. Ozcan C, Vayisoglu Y, Dogu O, Gorur K. The effect of intranasal injection of botulinum toxin A on the symptoms of vasomotor rhinitis. Am J Otolaryngol. 2006;27:314–8.
4. Rohrbach S, Junghans K, Köhler S, Laskawi R. Minimally invasive application of botulinum toxin A in patients with idiopathic rhinitis. Head Face Med. 2009;5:18. This study is the first clinical study presenting the effect of sponge-soaked application of botulinum toxin-A.
5. Bachert C. Persistent rhinitis—allergic or nonallergic? Allergy. 2004;59 Suppl 76:11–5. This review outlines how to differentiate allergic rhinitis from the non-allergic rhinitis and what is important to diagnose non-allergic rhinitis.
6. Shaari CM, Sanders I, Wu BL, Biller HF. Rhinorrhea is decreased in dogs after nasal application of botulinum toxin. Otolaryngol Head Neck Surg. 1995;112:566–71. This experimental study firstly showed the effect of BTX-A on nasal secretion.
7. Widdicombe JG. Neuroregulation of the nose and bronchi. Clin Exp Allergy. 1996;26 Suppl 3:32–5.
8. Ismi O, Ozcan C, Karabacak T, et al. Local of neurotrophin-3 in neuronal inflammation of allergic rhinitis: preliminary report. Balk Med J. 2015;32:364–70.
9. Tai CF, Baraniuk JM. A tale of two neurons in the upper airways: pain versus itch. Curr Allergy Asthma Rep. 2003;3:215–20.
10. Laing TA, Laing ME, O’Sullivan ST. Botulinum toxin for treatment of glandular hypersecretory disorders. J Plast Reconstr Aesthet Surg. 2008;61:1024–8.
11. Bentivoglio AR, Del Grande A, Perracca M, Ialonga T. Clinical differences between botulinum neurotoxin type A and B. Toxicon. 2015;107:77–84.
12. Tighe AP, Schiavo G. Botulinum neurotoxins: mechanism of action. Toxicon. 2013;67:87–93.
13. Naumann M, Jost W. Botulinum toxin treatment of secretory disorders. Mov Disord. 2004;19 suppl 8:137–41.
14. Persaud R, Garas G, Silva S, Stamatoglou C, Chatrath P, Patel K. An evidence-based review of botulinum toxin (Botox) applications in non-cosmetic head and neck conditions. J R Soc Med Sh Rep. 2013;4:10.
15. Naumann M, Dressler D, Hallett M, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders. Toxicon. 2013;67:141–52.
16. Laskawi R. The use of botulinum toxin in head and face medicine: an interdisciplinary field. Head Face Med. 2008;4:5.
17. Wen WD, Yuan F, Wang JL, Hou YP. Botulinum toxin therapy in the ovalbumin-sensitized rat. Neuroimmunomodulation. 2007;14:78–83.
18. Kim KS, Kim SS, Yoon JH, Han JW. The effect of botulinum toxin type A injection for intrinsic rhinitis. J Laryngol Otol. 1998;112:248–51.
19. Dykewicz MS, Hamilos DL. Rhinitis and sinusitis. J Allergy Clin Immunol. 2010;125:103–15.
20. Aoishi K, Takahashi H, Hato N, et al. Treatment of allergic rhinitis with intranasal infusion of botulinum toxin type A in mice. 2016; 147:132-6.
21. Rohrbach S, Olthoff A, Laskawi R, Giefer B, Götz W. Botulinum toxin type A induces apoptosis in glands of guinea pigs. Ann Otol Rhinol Laryngol. 2001;110:1045–50. This experimental study is the first study showing histological changes especially apoptosis of nasal glands after intranasal botulinum toxin application.
22. Gunes MS, Kulahli I, Kokoglu K, et al. Evaluation of the effect of intranasal infiltrated botulinum toxin-A on a model of allergic rhinitis in rabbits: an experimental study. Int J Pediatr Otorhinolaryngol. 2016;83:51–6.
23. Zhu Z, Stone HF, Thach TQ, Garcia L, Ruegg CL. A novel botulinum neurotoxin topical gel: treatment of allergic rhinitis in rats and comparative safety profile. Am J Rhinol Allergy. 2012;26:450–4.
24. Rohrbach S, Laskawi R. Minimally invasive application of Botulinum toxin type A in nasal hypersecretion. ORL J Otorhinolaryngol Relat Spec. 2001;63:382–4.
25. Unal M, Sevim S, Dogu O, Vayisoglu Y, Kanik Y. Effect of botulinum toxin type A on nasal symptoms in patients with allergic rhinitis: a double-blind, placebo-controlled clinical trial. Acta Otolaryngol. 2003;123:1060–3. This report firstly showed the effect of intraturbinal injection of BTX-A in allergic rhinitis patients.
26. Wang J, Chen F, Meng M, Zhang X, Chen Y, Huang W, et al. The influence of botulinum toxin type A on vasomotor rhinitis and morphological study. [Article in Chinese]. Lin Chuang Er Bi Yan Hou Ke Za Zhi. 2003;17:643–5.
27. Yang TY, Jung YG, Kim YH, Jang TY. A comparison of the effects of botulinum toxin A and steroid injection on nasal allergy. Otolaryngol Head Neck Surg. 2008;139:367–71.
28. Sapci T, Yazici S, Evcimik MF, et al. Investigation of the effects of intranasal botulinum toxin type A and ipratropium bromide nasal spray on nasal hypersecretion in idiopathic rhinitis without eosinophilia. Rhinology. 2008;46:45–51.
29. Nowak K, Szyfter W. Application of botulinum toxin A in chronic intrinsic rhinitis. [Article in Polish]. Otolaryngol Pol. 2011;65:103–5.
30. Braun T, Gürkov R, Kramer MF, Krause E. Septal injection of botulinum neurotoxin A for idiopathic rhinitis: a pilot study. Am J Otolaryngol. 2012;33:64–7. This article showed the effect of nasal septal BTX-A injection in idiopathic rhinitis patients.
31. Abtahi SM, Hashemi SM, Abtahi SM, Bastani B. Septal injection in comparison with inferior turbinates injection of botulinum toxin A in patients with allergic rhinitis. J Res Med Sci. 2013;18:400–4.
32. Hashemi SM, Okhovat A, Amini S, Pourghasemian M. Comparing the effects of botulinum toxin-A and cetirizine on the treatment of allergic rhinitis. Allergol Int. 2013;62:245–9.
33. Shemshadi H, Azimian M, Kamrani AAK, Onsori MA. Botulinum toxin type A on an intranasal sponge for chronic allergic rhinitis: randomized clinical trial. Iran Rehabil J. 2013;11:5–11.
34. Mozafarinia K, Abna M, Khanjani N. Effect of botulinum neurotoxin A injection into the submucoperichondrium of the nasal septum in reducing idiopathic non-allergic rhinitis and persistent allergic rhinitis. Iran J Otorhinolaryngol. 2015;27:253–9.
35. Pattanaik D, Lieberman P. Vasomotor rhinitis. Curr Allergy Asthma Rep. 2010;10:84–91.
36. Vayisoglu Y, Ozcan C, Pekdemir H, Gorur K, Pata YS, Camsari A. Autonomic nervous system evaluation using heart rate variability parameters in vasomotor rhinitis patients. J Otolaryngol. 2006;35:338–42.